Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SpinewayFRA:37S -2.01%46 EV-to-EBIT is -1.16 as of Aug. 21, 2026. GuruFocus rates FRA:37S with a GF Score™ of 46/100 and a GF Value™ of €33.33 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 472 Medical Devices & Instruments companies, Spineway ranks worse than 211864.19% on this metric.
The historical rank and industry rank for Spineway's EV-to-EBIT or its related term are showing as below:
FRA:37S'
s EV-to-EBIT Range Over the Past 10 Years
Min: -6.12 Med: -0.13 Max: 0.85
Current: -1.16
During the past 13 years, the highest EV-to-EBIT of Spineway was 0.85. The lowest was -6.12. And the median was -0.13.
FRA:37S's EV-to-EBIT is ranked worse than 100% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 19.665
vs FRA:37S: -1.16
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Spineway's Enterprise Value for the quarter that ended in Dec. 2025 was €3.11 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Spineway's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-2.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spineway EV-to-EBIT Related Terms
Spineway EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Spineway's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Spineway's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spineway EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Spineway's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Spineway's EV-to-EBIT falls into.
Spineway's current Enterprise Value is €2.69 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Spineway's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-2.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spineway (FRA:37S) has a EV-to-EBIT of -1.16 as of Aug. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Spineway and its competitors. According to the industry distribution chart, Spineway ranks #999999 out of 472 companies in the Medical Devices & Instruments industry.
Is Spineway's EV-to-EBIT too high?
Spineway's current EV-to-EBIT is -1.16. Based on the distribution chart, Spineway ranks #999999 out of 472 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Spineway has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Spineway's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Spineway ranks #999999 out of 472 companies for EV-to-EBIT. This places Spineway in the lower half of its industry. The industry median EV-to-EBIT is 19.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.67, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Spineway and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spineway's current EV-to-EBIT is -1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spineway stock overvalued right now?
Based on GuruFocus' analysis, Spineway (FRA:37S) is currently considered Possible Value Trap. The stock's GF Value™ is €33.33, compared to a current price of €0.13 — trading 99.6% below its estimated fair value. The current EV-to-EBIT is -1.16. Spineway's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Spineway (FRA:37S), the current EV-to-EBIT is -1.16 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spineway (FRA:37S) Overvalued in 2026?
Based on GuruFocus' analysis, Spineway stock appears to be undervalued.
The current stock price of €0.13 is trading 99.6% below its estimated GF Value™ of €33.33.
GuruFocus considers Spineway to be Possible Value Trap.
Key valuation signals for FRA:37S:
EV-to-EBIT: -1.16
GF Value™: €33.33 vs. price of €0.13 (99.6% below fair value)
No single metric tells the full story. See the FRA:37S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spineway designs produce and markets implant lines and ancillary surgical equipment used for the treatment of severe disorders of the spinal column. The group offers spinal systems, cervical and lumbar cages, cervical plates, bone substitutes, and other such medical instruments.
46GF Score
Get the complete analysis for FRA:37S
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:37S has been successfully added to your 
